Background {#Sec1}
==========

Multidrug resistant organisms are a major public health concern \[[@CR1], [@CR2]\]. There is an increase in the global detection of antibiotic resistant Enterobacteriaceae strains with antibiotic resistance observed to beta-lactams, fluoroquinolones, aminoglycosides and polymixins \[[@CR3]\]. Beta-lactam resistance mechanisms include outer membrane permeability changes, efflux pumps and enzymes that hydrolyse the antibiotic for example, the carbapenemases, including: the metallo-beta-lactamases (MBLs), NDM, IMP and VIM; the oxacillinases, OXA-48 and non-metallo-enzymes, *Klebsiella pneumoniae* carbapenemases (KPC) \[[@CR3]\]. The emergence of resistance to the broad-spectrum carbapenem group of antibiotics is particularly worrying as it limits treatment options and necessitates the need for the use of antibiotics like tigecycline and colistin which contribute to toxicity \[[@CR4]--[@CR6]\]. Carbapenemase-producing Enterobacteriaceae (CPE) are carbapenem-resistant Enterobacteriaceae (CRE) that are resistant to carbapenems due to carbapenemase production \[[@CR7]\]. Carbapenemases are beta-lactamases \[[@CR8]\] that hydrolyse almost all beta-lactams including the carbapenems \[[@CR3], [@CR9]\]. Carbapenemases were initially chromosomally-mediated in a few specific species, however majority are now plasmid-mediated, or both chromosomally- and plasmid-mediated \[[@CR10], [@CR11]\] resulting in horizontal transmission among various bacterial species and genera. The ability of these mobile genetic elements (plasmids) to acquire, harbour and disseminate multiple resistance genes contributes to the successful and aggressive spread of resistant organisms \[[@CR12]\]. The presence of these genes has been documented worldwide such as in Asia, Europe, Australia and Africa including South Africa \[[@CR13]--[@CR32]\]. In South Africa the first case of NDM in *Enterobacter cloacae* was reported in the Gauteng province in 2011 and then almost a year later in KwaZulu-Natal. *Klebsiella pneumoniae* isolates harbouring KPC, OXA-48 and OXA-181were reported in Gauteng 2011. An outbreak of OXA-181 in *Klebsiella pneumoniae* was documented in the Western Cape in 2012 and the presence of OXA-48, VIM and IMP in *Enterobacter cloacae* isolates isolated from patients in the Eastern Cape has also been reported \[[@CR27]--[@CR32]\]. The need to prevent the spread of these organisms is important, however, there are some obstacles. Many clinical laboratories do not routinely test for CRE resistance-mechanisms. They are therefore not able to differentiate between non-susceptible CREs (which may be as a result of carbapenemases or *via* combinations of ampicillin class C (AmpC) enzymes, extended-spectrum beta-lactamases (ESBL) and membrane impermeability), and CPEs (which are as a result of carbapenemase production exclusively) \[[@CR33]\]. Furthermore, the Clinical and Laboratory Standards Institute (CLSI) does not recommend molecular resistance-mechanism testing for clinical purposes \[[@CR34]\].

In this study, we evaluated1193 suspected CREs to estimate the prevalence of CPEs in our sample population in South Africa. This was not a surveillance study but nonetheless provided us with baseline information regarding the extent of CPEs in the country and the organisms producing them. We also evaluated one of the phenotypic methods routinely used for antimicrobial susceptibility testing (AST) to determine its efficacy and accuracy and report on its ability to screen for CREs based on confirmed CPE genes received at the reference laboratory.

Methods {#Sec2}
=======

The national Antimicrobial Resistance Laboratory (AMRL) for the public healthcare sector, which majority of the South African population have access to, have been testing referred suspected CPE isolates for the presence of selected carbapenemases. Clinically significant phenotypically identified carbapenem non-susceptible Enterobacteriaceae isolates were voluntarily submitted from 46 laboratories to the AMRL at the Centre for Opportunistic, Tropical and Hospital Infections (COTHI), National Institute for Communicable Diseases (NICD) for confirmation of carbapenemase-producing genes as part of a routine diagnostic programme. Isolates received for the period 2012--2015 were analysed; it is important to note that each isolate was analysed individually (for 179 patients, isolates from multiple sites and some repeats were submitted). When the isolate was received at the AMRL, organism identification was performed using automated systems (VITEK^®^ II (bioMèrieux, France) and/or the Microflex MALDI-ToF (Bruker Daltonik, GmbH) and antimicrobial susceptibility testing (AST) was carried out on the automated MicroScan^®^ Walkaway system (Siemens, USA) using the Gram-negative MIC Panel Type 44 (ertapenem 0.5--1μg/mL; doripenem 1--4μg/mL; imipenem 1--8 μg/mL; meropenem 1--8 μg/mL). The Sensititre instrument (Trek Diagnostic Systems, UK) was used to clarify and confirm questionable Microscan results (i.e. an isolate was phenotypically susceptible to the carbapenems although a carbapenemase was present). For this procedure, microtitre trays with two-fold dilutions of antibiotics were inoculated with a standardised inoculum of the bacteria and incubated under standardised conditions. The minimal inhibitory concentration (MIC) was recorded the next day as the lowest concentration of antimicrobial agent with no visible growth. The interpretation of susceptibility was done according to the Clinical and Laboratory Standards Institute (CLSI) guidelines \[[@CR34]\]. For genotypic testing, DNA was extracted using a crude boiling method at 95°C for 25 minutes for cell lysis. The supernatant was harvested and screened for *bla* ~NDM~, *bla* ~KPC~, *bla* ~OXA-48~ and its variants (OXA-162, 163, 244 245, 247, 181, 204, 232), *bla* ~GES~ (GES-1-9, 11)~,~ *bla* ~IMP~ (IMP-9, 16, 18, 22, 25) and *bla* ~VIM~ (VIM-1-36) using a multiplex real-time polymerase chain reaction (PCR) (LightCycler 480 II, Roche Applied Science, LightCycler 480 Probes Master kit and the individual LightMix Modular kits (Roche Diagnostics, IN, USA).

Statistical analyses were performed using Graph Pad Prism 5.

Results {#Sec3}
=======

In this study, in the period 2012--2015, we received 1193 suspected CREs to confirm CPE genes. We also evaluated the phenotypic method used for antimicrobial susceptibility testing and reporting of CREs.

From a total of 1193 isolates, 68 % (*n* = 812) harboured at least one or a combination of CPE genes. Of these, 469 (57 %) were *bla* ~NDM~-positive, 219 (26 %) were *bla* ~OXA-48~-positive (including variants), 89 (10 %) were *bla* ~VIM~-positive, 35 (4 %) were *bla* ~IMP~-positive, 18 (2 %) were *bla* ~GES~-positive and 11 (1 %) were *bla* ~KPC~-positive. Combinations consisted of *bla* ~NDM~- and *bla* ~OXA-48~-positive (*n* = 8), *bla* ~NDM~- and *bla* ~IMP~-positive (*n* = 4), *bla* ~NDM~- and *bla* ~VIM~-positive (*n* = 3), *bla* ~NDM~- and *bla* ~KPC~-positive, *bla* ~KPC~- and *bla* ~VIM~-positive, *bla* ~IMP~- and *bla* ~OXA-48~-positive, *bla* ~VIM~- and *bla* ~OXA-48~-positive (*n* = 2 each) and *bla* ~NDM~- and *bla* ~GES~-positive and *bla* ~GES~- and *bla* ~OXA-48~-positive (*n* = 1 each).

Majority of the carbapenemase producing isolates were *Klebsiella* spp. (71 %, *n* = 580) followed by *Enterobacter* spp. (12 %, *n* = 101), *Serratia marcescens* (7.8 %, *n* = 63), *Escherichia coli* (4 %, *n* = 35), *Citrobacter* spp. (3.9 %, *n* = 32), *Providencia* spp. (2.9 %, *n* = 24) and *Morganella morganii* and *Raoultella* spp. (0.4 %, *n* = 3, each). The predominating genotype in most organism species was *bla* ~NDM~ with the exception of *Enterobacter* spp. which also included *bla* ~IMP~. In *E. coli* the predominating genotype was *bla* ~OXA-48~ and its variants which were also commonly found in all other organisms except in *Providencia* spp., *Morganella morganii* and *Raoultella* spp. (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Organism and genotype information in carbapenemase producing isolates

Specimen types in the carbapenemase producing isolates were blood (32 %, *n* = 257), urine (21 %, *n* = 171), swabs (11 %, *n* = 87), body fluids (7 %, *n* = 59), catheter tip (4 %, *n* = 35), sputum (3 %, *n* = 30) and smaller percentages ranging from 0.1 % (*n* = 1) to 1.9 % (*n* = 16) for bone marrow, cerebrospinal fluid, stool, upper respiratory tract, lower respiratory tract and tissue specimens. Up to 26 % (*n* = 212) of the isolates specimen types were unknown or the data were not available (Fig. [2](#Fig2){ref-type="fig"}). There was no apparent correlation/relationship between specimen type and organism or specimen type and genotype.Fig. 2Specimen type and genotype information in carbapenemase producing isolates. *Citrobacter* spp.: NDM, *n* = 27; KPC, *n* = 3; OXA-48, *n* = 1; GES, *n* = 1. Enterobacter spp.: NDM, *n* = 31; KPC, *n* = 1; OXA-48, *n* = 29; IMP, *n* = 31; VIM, *n* = 9. E.coli: NDM, *n* = 11; OXA-48, *n* = 22, VIM, *n* = 2. Klebsiella spp.: NDM, *n* = 325; KPC, *n* = 7; OXA-48, *n* = 156; IMP, *n* = 2; VIM, *n* = 76; GES, *n* = 14. Morganella morganii: NDM, *n* = 3. Providencia spp.: NDM, *n* = 21, IMP, *n* = 2; VIM, *n* = 1. Raoultella spp.: NDM, *n* = 2. Serratia marcescens: NDM, *n* = 49; OXA-48, *n* = 11; GES, *n* = 3

*Bla* ~NDM~ predominated in the years 2012--2015 (71 %, *n* = 25; 49 %, *n* = 99; 50 %, *n* = 162 and 66 %, *n* = 183 respectively) followed by *bla* ~OXA-48~ and its variants (11 %, *n* = 4; 19 %, *n* = 38; 32 %, *n* = 104 and 26 %, *n* = 73 respectively). In 2013, 16 % (*n* = 32) were *bla* ~IMP~-positive whereas in 2014 and 2015 there were higher numbers of *bla* ~VIM~-positive isolates (14 %, *n* = 47 and 8 %, *n* = 22 respectively) (Fig. [3](#Fig3){ref-type="fig"}). Statistical analysis using the chi-squared test revealed that the change in resistance mechanisms from 2012 to 2015 was significant (*p* \< 0.0001) i.e. there was a significant increase in the number of genotypes detected from 2012 compared to 2015.Fig. 3Genotype information in carbapenemase producing isolates over the 3 year period. 2012 -- NDM *n* = 25, 71 %; KPC *n* = 2, 6 %; OXA-48 *n* = 4, 11 %; IMP *n* = 2, 6 %; VIM *n* = 2, 6 %; GES *n* = 0. 2013 -- NDM *n* = 99, 49 %; KPC *n* = 6, 3 %; OXA-48 *n* = 38, 19 %; IMP *n* = 32, 16 %; VIM *n* = 18, 9 %; GES *n* = 9, 4 %. 2014 -- NDM *n* = 162, 50 %; KPC *n* = 3, 1 %; OXA-48 *n* = 104, 32 %;IMP *n* = 1, 0.3 %;VIM *n* = 47, 14 %;GES *n* = 9, 3 %. 2015 -- NDM *n* = 183, 66 %; KPC *n* = 0; OXA-48 *n* = 73, 26 %; IMP *n* = 0; VIM *n* = 22, 8 %; GES *n* = 0

Antimicrobial susceptibility testing profiles of these carbapenemase producing isolates were analysed. Ertapenem proved to be a reliable indicator of carbapenemase production. Ertapenem non-susceptibility was observed in 98 % (*n* = 794) of the carbapenemase producing isolates indicating that the phenotypic method used was fairly sensitive. Eighteen (2 %) isolates produced an ertapenem-susceptible result although a CPE gene was present (*bla* ~VIM,~ *n* = 10; *bla* ~NDM,~ *n* = 4; *bla* ~VIM,~ and *bla* ~OXA-48~-like~,~ *n* = 1; *bla* ~IMP,~ *n* = 1; *bla* ~GES,~ *n* = 1 and *bla* ~OXA-48~ and variants~,~ *n* = 1). Three of these isolates were fully susceptible to the third and fourth generation cephalosporins (cefotaxime, ceftazidime and cefepime) as well as to the remaining carbapenems (imipenem, meropenem and doripenem). These isolates contained the following genes: *bla* ~NDM~ (*n* = 2) and *bla* ~OXA-48~ and variants (*n* = 1). Interestingly, 12 of these ertapenem-susceptible isolates showed non-susceptibility to imipenem; two of these were also non-susceptible to meropenem. Majority (92 %, *n* = 11) of these were *bla* ~VIM~-positive with one isolate also positive for *bla* ~OXA-48~ and its variants. The remaining two isolates contained *bla* ~NDM~ (Table [1](#Tab1){ref-type="table"})~.~ Of the carbapenem non-susceptible carbapenemase producing isolates, one isolate was susceptible to cefotaxime, 12 were susceptible to ceftazidime and 23 were susceptible to cefepime. The carbapenemase types are seen in Table [2](#Tab2){ref-type="table"}. The percentage susceptibility for the cephalosporins and carbapenems is presented in Fig. [4](#Fig4){ref-type="fig"}. The susceptibility rates for cefotaxime, ceftazidime and cefepime decreased over the three year period. There was a slight increase in the percentage susceptibility for ertapenem over the three year period: 1 % (*n* = 2) in 2013, 1.6 % (*n* = 5) in 2014 and 3.72 % (*n* = 10) in 2015), however overall the percentage susceptibility was low.Table 1Minimal inhibitory concentrations (MIC) of ertapenem susceptible carbapenemase producing isolatesSample IDORGANISMNDMKPCOXA-48 & variantsIMPVIMGESCefepime MICCefotaxime MICCeftazidime MICErtapenem MICImipenem MICMeropenem MICDoripenem MICML0148.2*Enterobacter cloacae*\-\--+\--\>16\>32\>16\<=0.5\<=2\<=1Not testedML0191*Klebsiella pneumoniae*\-\-\-\--+8\>32\>16\<=0.5\<=2\<=1Not testedML0440*Klebsiella pneumoniae*\-\-\--+-16\>32\>16\<=0.542Not testedML0446*Klebsiella pneumoniae*\-\-\--+-\<=1\<=1\<=1\<=0.5\<=2\<=1Not testedML0848*Klebsiella pneumoniae*\-\-\--+-\>16\>32\>16\<=0.54\<=1\<=1ML0917*Providencia rettgeri*+\-\-\-\--\<=1\<=1\<=1\<=0.5\<=1\<=1\<=1ML0926*Escherichia coli*+\-\-\-\--\<=1\<=1\<=1\<=0.5\<=1\<=1\<=1ML0930*Klebsiella pneumoniae*\-\-\--+-\>16\>32\>16\<=0.54\<=1\<=1ML1002*Providencia rettgeri*+\-\-\-\--832\>16\<=0.5\>822ML1007*Klebsiella pneumoniae*\-\-\--+-\>16\>32\>16\<=0.54\<=12ML1161*Klebsiella pneumoniae*\--+\-\--\>16\>32\>16\<=0.5\<=2\<=1Not testedML1187*Escherichia coli*\--+-+-2816\<=0.54\<=1\<=1ML1189*Klebsiella pneumoniae*\-\-\--+-\>16\>32\>16\<=0.52\<=1\<=1ML1219*Klebsiella pneumoniae*\-\-\--+-16\>32\>16\<=0.52\<=1\<=1ML1279*Klebsiella pneumoniae*\-\-\--+-\>16\>32\>16\<=0.52\<=1\<=1ML1296*Klebsiella pneumoniae*\-\-\--+-\>16\>32\>16\<=0.54\<=1\<=1ML1340*Morganella morganii*+\-\-\-\--8\>32\>16\<=0.58\<=12ML1354*Klebsiella pneumoniae*\-\-\--+-\>16\>32\>16\<=0.54\<=12CLSI breakpoints: Cefepime: \<=2 -- Susceptible, 4-8 -- Susceptible-Dose Dependant, \> = 16 -- Resistant; Cefotaxime: \<=1 - Susceptible, 2 -- Intermediate, \> = 4 -- Resistant; Ceftazidime: \<=4 - - Susceptible, 8 -- Intermediate, \> = 16 -- Resistant; Ertapenem: \<=0.5- Susceptible, 1 -- Intermediate, \> = 2 -- Resistant; Imipenem/Meropenem/Doripenem: \<=1 -- Susceptible, 2 -- Intermediate, \> = 4 Resistant \[[@CR34]\] Table 2Minimal Inhibitory Concentrations (MIC) of carbapenem non-susceptible, cephalosporin susceptible carbapenemase producing isolatesSample IDOrganismNDMKPCOXA-48& variantsIMPVIMGESCefepime MICCefotaxime MICCeftazidime MICErtapenem MICImipenem MICMeropenem MICDoripenem MICML0056*Klebsiella oxytoca*\--+\-\--168\<=1\>4\>8\>8Not testedML0273*Klebsiella pneumoniae*\--+\-\--24\<=1\>1\>8\>8\>4ML0344*Providencia rettgeri*+\--+\--832\>164\>84Not testedML0432*Serratia marcescens*\-\-\-\--+\<=142\>4\>8\>8Not testedML0484*Klebsiella pneumoniae*\--+\-\--\<=12\<=1\>1\>844ML0513*Klebsiella pneumoniae*\--+\-\--\<=14\<=1\>1484ML0514*Klebsiella pneumoniae*\--+\-\--\<=12\<=1\>1244ML0515*Klebsiella pneumoniae*\--+\-\--\<=12\<=1\>14\>8\>4ML0517*Klebsiella pneumoniae*\--++\--\<=12\<=1\>1444ML0634*Serratia marcescens*\--+\-\--8\>3216\>1\>8\>8\>4ML0794*Klebsiella pneumoniae*\--+\-\--\<=1\<=1\<=1\>122\<=1ML0825*Serratia marcescens*\--+\-\--8\>3216\>1\>8\>8\>4ML0841*Serratia marcescens*\-\-\-\--+8328\>1\>8\>8\>4ML0878*Providencia rettgeri*+\-\-\-\--832\>16\>1\>8\>8\>4ML0883*Serratia marcescens*\--+\-\--8\>3216\>18\>8\>4ML0886*Serratia marcescens*\--+\-\--8\>32\>16\>1\>8\>8\>4ML0905*Serratia marcescens*\--+\-\--842\>18\>8\>4ML0910*Enterobacter gergoviae*\--+\-\--44\<=1\>12\>8\>4ML0918*Providencia rettgeri*+\-\-\-\--832\>16\>1\>88\>4ML0976*Escherichia coli*\--+\-\--\<=12\<=1\>1244ML0999*Providencia rettgeri*+\-\-\-\--832\>16\>1\>8\>8\>4ML1167*Serratia marcescens*\--+\-\--8\>3216\>1\>8\>8\>4ML1176*Providencia rettgeri*+\-\-\-\--816\>161\>88\>4ML1411*Klebsiella pneumoniae*\--+\-\--8\>328\>1824CLSI breakpoints: Cefepime: \<=2 -- Susceptible, 4-8 -- Susceptible-Dose Dependant, \> = 16 -- Resistant; Cefotaxime: \<=1 - Susceptible, 2 -- Intermediate, \> = 4 -- Resistant; Ceftazidime: \<=4 - - Susceptible, 8 -- Intermediate, \> = 16 -- Resistant; Ertapenem: \<=0.5- Susceptible, 1 -- Intermediate, \> = 2 -- Resistant; Imipenem/Meropenem/Doripenem: \<=1 -- Susceptible, 2 -- Intermediate, \> = 4 Resistant \[[@CR34]\] Fig. 4Percentage susceptibility to carbapenems and cephalosporins in carbapenemase producing isolates, 2013-2015. Data for 2012 was limited and was excluded from this analysis

Imipenem and meropenem were fairly good indicators of carbapenemase production with non-susceptibility observed in 77 % (*n* = 643) and 79 % (*n* = 661) of the carbapenemase producing isolates, respectively. A decrease in the percentage susceptibility was also seen for imipenem, meropenem and doripenem over time. It should be noted that the instrument panel did not initially consist of doripenem and it was therefore not tested for, accounting for the low percentage obtained in 2013.

Of the 381 non-CPE isolates 333 (87 %) were phenotypically non-susceptible to ertapenem; 88 (23 %) were non-susceptible to imipenem and 155 (41 %) were non-susceptible to meropenem indicating that the phenotypic method used lacks specificity particularly in the case of ertapenem. Majority of the non-CPE isolates were *Klebsiella* spp. (49 %, *n* = 185) followed by *Enterobacter* spp. (40 %, *n* = 154), *Escherichia coli* (6 %, *n* = 23), *Morganella morganii* (2.7 %, *n* = 10), *Serratia marcescens* (1.5 %, *n* = 6), *Proteus mirabilis.* (0.5 %, *n* = 2) and *Citrobacter freundii*. (0.3 %, *n* = 1). Specimen types varied: urine (27 %, *n* = 102), blood (20 %, *n* = 77), swabs (16 %, *n* = 60), body fluids (7 %, *n* = 28), catheter tip (4 %, *n* = 16), sputum (3.7 %, *n* = 14) and smaller percentages ranging from 0.3 % (*n* = 1) to 1.6 % (*n* = 6) for cerebrospinal fluid, upper respiratory tract, lower respiratory tract and tissue specimens. Up to 18 % (*n* = 70) of the isolates specimen types were unknown or the data were not available.

The overall antimicrobial susceptibility and PCR (gold standard) results were compared to determine the sensitivity, specificity, positive predictive value and negative predictive value of the phenotypic method routinely used (i.e. the MicroScan^®^ Walkaway system). The sensitivities, specificities, positive and negative predicted values for ertapenem, imipenem and meropenem can be seen in Table [3](#Tab3){ref-type="table"}. The use of doripenem as a denominator was omitted as it was not included in the AST panel for all isolates tested.Table 3Sensitivity, specificity, positive and negative predictive values of the microscan walkaway systemAntibioticSensitivity (%)Specificity (%)Positive predictive value (%)Negative predictive value (%)Ertapenem98137073Imipenem76778860Meropenem78598056

Discussion {#Sec4}
==========

This study is a snapshot of the distribution of CPEs over a period of three years and does not represent the current burden of CPEs in South Africa. This study elucidates the current prevalent circulating CPE types. We observed that a high percentage (68 %) of the isolates harboured at least one or a combination of carbapenemase-producing genes. It should be noted that although genotypic methods are remarkably reliable, there are some potential limitations. False-negative results may be obtained as genes may not be detected due to the presence of genetic variants and/or rare carbapenemase types that were not included in the screening e.g. SPM, SIM, IMI etc. This could suggest that variants and other carbapenemases may potentially have been missed suggesting that the actual prevalence of CPEs in our study population could be higher. This is worrisome as the rate of CPEs in South Africa is increasing as indicated by the number of studies reporting occurrences and outbreaks \[[@CR27]--[@CR32]\].

Majority of the CPE isolates (those harbouring carbapenemases) were *Klebsiella* spp*.* (71 %, *n* = 580) followed by *Enterobacter* spp. (12 %, *n* = 101), *Escherichia coli* (4 %, *n* = 35) and *Citrobacter* spp. (3.9 %, *n* = 32) were also present to a smaller extent. Interestingly, we observed that 10.7 % (*n* = 90) of the carbapenemase producing isolates belonged to one of the following organisms: *Serratia marcescens* (7.8 %, *n* = 63), *Providencia* spp. (2.9 %, *n* = 24) and *Morganella morganii* (0.4 %, *n* = 3). Carbapenem resistance is particularly worrying in organisms such as these as well as *Proteus* spp. as these organisms are intrinsically resistant to colistin and if carbapenem cannot be used for treatment, the management of patients infected with these organisms is all the more challenging. Overall, in addition to the carbapenems other antibiotics were analysed for all carbapenemase producing isolates; with the exception of a few (amikacin, tigecycline and colistin) which showed high susceptibility, majority of the isolates showed varying degrees of resistance to the other antibiotics (ciprofloxacin, gentamicin, trimethoprim/sulfamethoxazole, pipercillin/tazobactam, ampicillin/sulbactam, aztroenam, cefotaxime, ceftazidime, cefepime and cefpodoxime). Resistance to these antibiotics may also be due to the presence of AmpCs and/or ESBLs. Screening for these would provide useful information for management purposes, however this was not done.

The most predominant genotype in the carbapenemase producing Enterobacteriaceae group was *bla* ~NDM~ (56 %, *n* = 469) followed by *bla* ~OXA-48~ and its variants (26 %, *n* = 219). *Bla* ~VIM,~ *bla* ~IMP,~ *bla* ~GES~ and *bla* ~KPC~ were also present but on a smaller scale (11 %, *n* = 89; 4 %, *n* = 35; 2 %, *n* = 18 and 1 %, *n* = 11 respectively). This is consistent with previous findings in South Africa where these genotypes have been confirmed in both the public and private sector hospitals in various provinces \[[@CR27], [@CR28], [@CR30]--[@CR32], [@CR35]\]. There was a marked increase in *bla* ~NDM~ and *bla* ~OXA-48~ and its variants from 2012 to 2015. This is a matter of concern as it may indicate a possible emergence of these genotypes which have the potential to become endemic. The significant increase in the number of genotypes detected from 2012 compared to 2015 further highlights this.

Phenotypically, ertapenem non-susceptibility is the most sensitive indicator of carbapenemase production \[[@CR34]\]. This was observed in our study with ertapenem non-susceptibility observed in 98 % of the carbapenemase producing isolates. Of these isolates approximately 3 % (*n* = 24) were non-susceptible to ertapenem but susceptible to the cephalosporins. According to the Clinical and Laboratory Standards Institute, isolates displaying non-susceptibility to ertapenem usually also test resistant to one or more cephalosporin subclass III agents (e.g. cefoperazone, cefotaxime, ceftazidime and ceftriaxone), however some isolates producing carbapenemases still continue to test susceptible to these cephalosporins \[[@CR34]\], a possible explanation for our outcomes. In summary, isolates displaying ertapenem-non-susceptibility and cephalosporin-susceptibility may often be OXA-48 producers without harbouring an ESBL, which could possibly be the case here. Three isolates were fully susceptible to the third and fourth generation cephalosporins as well as to imipenem, meropenem and doripenem. This is interesting because except for CREs that are OXA-48-like producers, most Enterobacteriaceae that produce carbapenemases are generally resistant to more than one antibiotic and resistant to third generation cephalosporins \[[@CR33]\]. One of these isolates was an OXA-48 producer but the other two have shown to produce NDM, suggesting that some organisms do not conform to the traditional behaviour and patient management could perhaps be on an individual basis depending on AST profiles and resistance mechanisms. It should be noted that although the phenotypic result was confirmed with two methodologies (Microscan and Sensititre), the molecular result was only indicative of the multiplex real-time PCR used and alternative primers were not employed. Moreover, sequencing of *bla* ~NDM~ was not performed which would further provide subtype information. Non-traditional AST profiles were also seen in other carbapenemase producing isolates which were carbapenem non-susceptible but susceptible to cefotaxime, ceftazidime or cefepime (Table [2](#Tab2){ref-type="table"}). Majority of these were OXA-48 producers. Furthermore, it was observed that a small percentage (1.5 %, *n* = 12) of ertapenem-susceptible isolates showed non-susceptibility to imipenem with a further subset (0.3 %, *n* = 2) being non-susceptible to meropenem as well. Majority of these were VIM-producers suggesting that low MICs to ertapenem can be typical of certain VIM types, as VIM-producers have variable kinetics for the different carbapenems. Hence there is heterogeneity in expression within the same clone and amongst different species \[[@CR36], [@CR37]\] and may in some instances result in some VIM-types not being detected phenotypically. Two percent of the carbapenemase producing isolates displayed fully carbapenem susceptible profiles. Previous studies have shown that the MIC breakpoints for carbapenems in particular, imipenem and meropenem were not elevated and in the susceptibility range of \<1 underscoring the difficulties in identifying metallo-β-carbapenemase- producing organisms primarily based on MIC results \[[@CR16], [@CR32]\].

While ertapenem has shown to be a reliable indicator of resistance in the carbapenemase producing Enterobacteriaceae group, phenotypic methods may not be ideal as observed in the non-CPE group as indicated by the high percentage (87 %) of non-CPE ertapenem-non-susceptible isolates indicating that this method lacks specificity. Imipenem and meropenem showed better specificity (23 % and 41 %, respectively) suggesting that all three antibiotics results should be used to enhance specificity for CRE detection. It should be noted however, that in instances where the phenotypic method indicates resistance and the PCR result is negative for all genes tested, resistance may be due to other carbapenemases, AmpC and or ESBL gene/s not screened for by the PCR. Alternatively, other mechanisms of resistance may be present e.g. efflux pumps and porin mutations. The former statement may be supported for example by the low cefoxitin susceptibility rate (10.8 %) suggesting that plasmid-mediated AmpC enzymes are very prevalent in our sample population. Similarly, the low susceptibility rates for the penicillins and cephalosprins (0.6--13 %) are indicative of ESBLs. We have not screened for these. However, the possibility remains that these isolates could in fact be non-CPE. This is worrying as phenotypic methods are routinely utilised and if ertapenem non-susceptibility is strictly used as an indication to treat patients with carbapenems even though a carbapenemase is not present, this would result in further implications towards potential antimicrobial resistance. This stresses the need for specific tests that can routinely be used.

Overall the phenotypic method used for the detection of carbapenemase production was highly sensitive for ertapenem (98 %) but the specificity was low (13 %), an indication that the method may possibly be over-reporting results potentially influencing clinicians to prescribe unnecessary antibiotics. For imipenem and meropenem, the specificities were satisfactory but the sensitivities were not. These antibiotics would therefore not be the ideal antibiotic of choice for this purpose.

Conclusion {#Sec5}
==========

We have shown an increase in carbapenemase-producing Enterobacteriaceae over a three year period with close to 40 % of all isolates received being *bla* ~NDM~-positive. Controlling the spread and limiting the impact of CPEs in South Africa will require intensive efforts in both the public and private healthcare sectors. The use of phenotypic methods for detection of CPEs using ertapenem is sensitive but lacks specificity and can be used if there is no access to molecular methods. However, conventional AST methods coupled with molecular genotypic testing for the detection of carbapenemase-producing Enterobacteriaceae is more definitive and therefore advantageous.

AmpC

:   Ampicillin class C (AmpC)

AST

:   Antimicrobial susceptibility testing

CLSI

:   Clinical and Laboratory Standards Institute

CPE

:   Carbapenemase-producing enterobacteriaceae

CRE

:   Carbapenem-resistant enterobacteriaceae

ESBL

:   Extended-spectrum beta-lactamases (ESBL)

KPC

:   *Klebsiella pneumoniae* carbapenemases

MBL

:   Metallo-beta-lactamases

MIC

:   Minimal inhibitory concentration

PCR

:   Polymerase chain reaction
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